

Local Coverage Article: Billing and Coding: MoIDX: CYP2C9 and/or VKORC1 Gene Testing for Warfarin Response (A53524)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATE(S)
Palmetto GBA	A and B MAC	10111 - MAC A	J - J	Alabama
Palmetto GBA	A and B MAC	10112 - MAC B	J - J	Alabama
Palmetto GBA	A and B MAC	10211 - MAC A	J - J	Georgia
Palmetto GBA	A and B MAC	10212 - MAC B	J - J	Georgia
Palmetto GBA	A and B MAC	10311 - MAC A	J - J	Tennessee
Palmetto GBA	A and B MAC	10312 - MAC B	J - J	Tennessee
Palmetto GBA	A and B and HHH MAC	11201 - MAC A	J - M	South Carolina
Palmetto GBA	A and B and HHH MAC	11202 - MAC B	J - M	South Carolina
Palmetto GBA	A and B and HHH MAC	11301 - MAC A	J - M	Virginia
Palmetto GBA	A and B and HHH MAC	11302 - MAC B	J - M	Virginia
Palmetto GBA	A and B and HHH MAC	11401 - MAC A	J - M	West Virginia
Palmetto GBA	A and B and HHH MAC	11402 - MAC B	J - M	West Virginia
Palmetto GBA	A and B and HHH MAC	11501 - MAC A	J - M	North Carolina
Palmetto GBA	A and B and HHH MAC	11502 - MAC B	J - M	North Carolina

Article Information

General Information

Article ID

A53524

Original Effective Date

10/01/2015

Article Title

Billing and Coding: MoIDX: CYP2C9 and/or VKORC1
Gene Testing for Warfarin Response

Revision Effective Date

12/12/2019

Article Type

Billing and Coding

Revision Ending Date

N/A

**AMA CPT / ADA CDT / AHA NUBC Copyright
Statement****Retirement Date**

N/A

CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Current Dental Terminology © 2019 American Dental Association. All rights reserved.

Copyright © 2019, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com.

CMS National Coverage Policy

CMS IOM Pub 100-04 Medicare Claims Processing CR 6715, Pharmacogenomic Testing for Warfarin Response

Article Guidance

Article Text:

Effective for dates of service on and after 01/01/2013

Based on NCD 90.1 - Pharmacogenomic Testing for Warfarin Response, gene testing on CYP2C9 and/or VKORC1 will only be covered through coverage with evidence development (CED). Testing will be limited to once in a lifetime per beneficiary. MoIDX will reimburse ONLY genetic testing services for beneficiaries who meet the NCD criteria and are enrolled in a clinical trial.

Lab providers that perform services on eligible beneficiaries and described by CPT[®] codes 81227 and 81355 must submit the following claim items:

- **HCPCS code:** G9143- warfarin responsiveness testing
- **ICD-10-CM code:** Z00.6-Encounter for examination for normal comparison and control in clinical research program
- **HCPCS modifier QO** - Investigational clinical service provided in a clinical research study that is in an approved clinical research study

For CPT[®] non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information.

- Enter the appropriate DEX Z-Code[™] identifier adjacent to the CPT[®] code in the comment/narrative field for the following Part B claim field/types:
 - Loop 2400 or SV101-7 for the 5010A1 837P
 - Box 19 for paper claim
- Enter the appropriate DEX Z-Code[™] identifier adjacent to the CPT[®] code in the comment/narrative field for the following Part A claim field/types:
 - Line SV202-7 for 837I electronic claim
 - Block 80 for the UB04 claim form

Note:

1. Report only G9143 and 1 UOS. Do NOT report CPT[®] code(s) 81227 and/or 81355 on the claim
2. Report only 1 ID on the claim
3. To facilitate payment, please add the voluntarily reported 8-digit clinical trial number

References:

Pub 100-04 Medicare Claims Processing, CR#6715 and 7806 NCD 90.1 - Pharmacogenomic Testing for Warfarin Response

Coding Information

CPT/HCPCS Codes

Group 1 Paragraph:

For warfarin response pharmacogenomics testing the following HCPCS code should be used and reported as a single unit of service regardless of how many genes are analyzed or which genes are analyzed.

Group 1 Codes:

CODE	DESCRIPTION
G9143	WARFARIN RESPONSIVENESS TESTING BY GENETIC TECHNIQUE USING ANY

CODE	DESCRIPTION
	METHOD, ANY NUMBER OF SPECIMEN(S)

Group 2 Paragraph:

The following codes should not be used to report pharmacogenomic testing for warfarin response, regardless of whether the test assesses CYP2C9 and / or VKORC.

Group 2 Codes:

CODE	DESCRIPTION
81227	CYP2C9 (CYTOCHROME P450, FAMILY 2, SUBFAMILY C, POLYPEPTIDE 9) (EG, DRUG METABOLISM), GENE ANALYSIS, COMMON VARIANTS (EG, *2, *3, *5, *6)
81355	VKORC1 (VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1) (EG, WARFARIN METABOLISM), GENE ANALYSIS, COMMON VARIANT(S) (EG, -1639G>A, C.173+1000C>T)

CPT/HCPCS Modifiers

Group 1 Paragraph:

N/A

Group 1 Codes:

CODE	DESCRIPTION
Q0	INVESTIGATIONAL CLINICAL SERVICE PROVIDED IN A CLINICAL RESEARCH STUDY THAT IS IN AN APPROVED CLINICAL RESEARCH STUDY

ICD-10 Codes that Support Medical Necessity

Group 1 Paragraph:

Z00.6

Group 1 Codes:

N/A

ICD-10 Codes that DO NOT Support Medical Necessity

N/A

Additional ICD-10 Information

N/A

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

N/A

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

Other Coding Information

N/A

Revision History Information

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION
12/12/2019	R10	Under CMS National Coverage Policy removed the CMS IOM Pub 100-04 Medicare Claims Processing CR 7806, Extracorporeal Photopheresis regulation.
10/31/2019	R9	<p>This article is being revised in order to adhere to CMS requirements per chapter 13, section 13.5.1 of the Program Integrity Manual, to remove all coding from LCDs and incorporate into related Billing and Coding Articles.</p> <p>Under Article Title changed the title to "Billing and Coding: MoIDX: CYP2C9 and/or VKORC1 Gene Testing for Warfarin Response". Under Article Text – References added the regulations to the CMS National Coverage Policy section. Under CPT/HCPCS Codes Group 1: Paragraph added the verbiage "For warfarin response pharmacogenomics testing the following HCPCS code should be used and reported as a single unit of service regardless of how many genes are analyzed or which genes are analyzed." Under CPT/HCPCS Codes Group 1: Codes added HCPCS code G9143. Under CPT/HCPCS Codes Group 2: Paragraph added the verbiage "The following codes should not be used to report pharmacogenomic testing for warfarin response, regardless of whether the test assesses CYP2C9 and / or VKORC." Under CPT/HCPCS Codes Group 2: Codes added CPT[®] codes 81227 and 81355. Under CPT/HCPCS</p>

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION
		Modifiers Group 1: Codes added modifier Q0. Formatting was corrected and CPT® was inserted throughout the article where applicable.
04/12/2018	R8	Conducted annual validation and corrected bullet issues. No change in article content.
02/26/2018	R7	The Jurisdiction "J" Part A and Part B Contracts for Alabama (10111/10112), Georgia (10211/10212) and Tennessee (10311/10312) are now being serviced by Palmetto GBA. Effective 02/26/18, these 6 contract numbers are being added to this article. No coverage, coding or other substantive changes (beyond the addition of the 6 Part A and B contract numbers) have been completed in this revision.
04/27/2017	R6	Annual review completed. Updated Part-A & Part B billing instructions.
01/14/2016	R5	Corrected typo. Moved Z00.6 from the Non-Covered ICD-10 Codes group section to the covered.
01/14/2016	R4	Replaced Palmetto with MolDX, removed reference of ICD 9 CM code and removed the word Projected in front of ICD 10 CM code.
07/09/2015	R3	Added ICD-10 code Z00.6 to ICD-10 code field.
10/01/2015	R2	Updated Annual Review date.
10/01/2015	R1	Added ICD-10 code per CR 7806.

Associated Documents

Related Local Coverage Document(s)

N/A

Related National Coverage Document(s)

N/A

Statutory Requirements URL(s)

N/A

Rules and Regulations URL(s)

N/A

CMS Manual Explanations URL(s)

N/A

Other URL(s)

N/A

Public Version(s)

Updated on 12/03/2019 with effective dates 12/12/2019 - N/A

Updated on 10/24/2019 with effective dates 10/31/2019 - N/A

Updated on 04/05/2018 with effective dates 04/12/2018 - N/A

Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A